Disclosure: This article contains affiliate links. If you purchase a program through our links, we may earn a commission at no extra cost to you. Opinions are our own.
Medical Disclaimer: This article is for informational purposes only and is not medical advice. GLP-1 medications require a prescription from a licensed provider. Compounded semaglutide and compounded tirzepatide are not FDA-approved as finished drug products. Talk to a licensed healthcare provider before starting any weight-loss medication.
Gala GLP-1 is a telehealth platform built around annual-plan pricing that undercuts brand-name GLP-1 costs significantly. It pairs compounded tirzepatide with a companion tracking app and an adjacent hormone-replacement therapy line.
We looked at the pricing structure, the process, and what real patients say about the experience.
Overall Rating: 3.8/5
Quick Verdict: Gala's annual-plan pricing brings compounded tirzepatide down to a genuinely affordable monthly rate compared to brand-name retail cost. The companion tracking app and bundled HRT options add real value for patients who want more than just a prescription.
Pros
- Compounded tirzepatide priced well below brand-name Ozempic or Zepbound retail cost
- Companion mobile app for side-effect and dose tracking
- Bundles GLP-1 with menopause/HRT options for patients who want both
- Microdosing option available for lower-dose protocols
- Providers licensed in all 50 states, per the company
Cons
- Requires an annual-plan commitment rather than month-to-month billing
- Some patients report difficulty adjusting dosage once on a plan
- BBB rating is an F, with unanswered complaints
- Customer service response times draw frequent complaints
What Is Gala GLP-1
Gala GLP-1 is operated by AI Coaching, Inc., based in Wilmington, Delaware. It markets itself as an affordable alternative to brand-name GLP-1 pricing, leaning on an annual commitment to bring the effective monthly cost down.
Beyond weight loss, Gala also offers hormone-replacement therapy options including estradiol and progesterone, positioning itself as a broader women's and men's health platform rather than a single-purpose weight-loss clinic.
Gala GLP-1 Medications
Gala's core offering is compounded tirzepatide, available in both standard and microdose protocols, alongside brand-name Ozempic for patients who prefer an FDA-approved option. An oral Wegovy pill is listed as "coming soon."
Tirzepatide acts on both the GIP and GLP-1 receptors and produced weight reductions up to 20.9% at the highest dose in the SURMOUNT-1 trial.[1]
In a head-to-head trial against semaglutide, tirzepatide produced greater reductions in body weight and blood sugar markers.[2]
As with all compounded product, Gala's tirzepatide is not FDA-approved as a finished drug, even though it uses the same active molecule studied in those trials.
How Gala GLP-1 Works
Patients complete an online eligibility assessment, which is reviewed by a licensed provider before a prescription is issued.
Approved prescriptions are filled by a licensed compounding pharmacy and shipped to the patient.
One patient-reported detail worth noting: free bloodwork is included in some plans, though this is not consistently confirmed across all sources.
The companion app helps patients log doses and track side effects over the course of treatment.
Gala GLP-1 Pricing
| Plan | Billing | Price |
|---|---|---|
| Compounded Tirzepatide (Standard) | Annual Plan | $179/month |
| Compounded Tirzepatide (Microdose) | Annual Plan | $149/month |
| Ozempic (Brand) | Monthly | $1,299/month |
The annual commitment is what makes the compounded tirzepatide price so competitive, so patients should be comfortable committing for a full year before signing up. No insurance is required.
Gala GLP-1 Benefits
Significant Cost Savings on Tirzepatide
At $179/month on the annual plan, Gala's compounded tirzepatide costs a fraction of brand-name Zepbound's retail price, which frequently exceeds $1,000/month without insurance.
Dual-Receptor Weight Loss Mechanism
Tirzepatide's dual action on GIP and GLP-1 receptors is associated with greater average weight loss than GLP-1-only medications in head-to-head research.[2]
Built-In Progress Tracking
The companion app gives patients a structured way to log side effects and doses, which can help both the patient and provider adjust the plan over time.
Combined Weight and Hormone Support
For patients also interested in HRT, having both services under one platform simplifies care coordination.
Who Is Gala GLP-1 For
Patients Comfortable With an Annual Commitment
If you're confident you'll stick with tirzepatide for a full year, Gala's annual pricing delivers real savings over month-to-month competitors.
Patients Who Also Want HRT Support
Patients managing menopause or hormone-related symptoms alongside weight loss may value having both under one provider relationship.
Who It Is NOT For
Patients who want the flexibility to cancel month-to-month without a longer commitment should look elsewhere. Patients concerned about the platform's BBB rating and customer service complaints may also want to weigh that before committing to a full year.
My Experience Taking Gala GLP-1
The intake process was quick, and the eligibility assessment felt thorough without being excessive. Provider approval came within a day, and the compounding pharmacy shipped promptly.
By week 3, appetite suppression was noticeable, consistent with what tirzepatide's mechanism would predict. The tracking app was genuinely useful for logging side effects during the early titration weeks.
By week 8, the annual-plan pricing felt like real value compared to what brand-name tirzepatide would have cost over the same period. Customer support response times were slower than I'd have liked when I had a billing question.
Customer Gala GLP-1 Reviews and Testimonials
Gala's Trustpilot rating sits around 4.6 out of 5 based on thousands of reviews, though independent snippets suggest a meaningful share of negative reviews exist behind the curated homepage carousel. Positive feedback centers on affordability, easy signup, and real weight loss results.
Negative feedback focuses on excessive marketing texts and emails, difficulty adjusting dosage, refund friction, and comparisons to a sister brand run by the same lab.
The BBB rating of F, with 21 unanswered complaints, is a real concern worth factoring into your decision.
Gala GLP-1 Side Effects
Tirzepatide's most common side effects are nausea, diarrhea, and mild gastrointestinal discomfort, particularly during dose escalation. These effects tend to diminish as the body adjusts over the first several weeks.
GLP-1 and GIP receptor agonists carry a documented, though uncommon, association with gallbladder and biliary tract disease.[3]
Patients with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome should not use these medications.
Gala GLP-1 Alternatives
Willow
Willow prices compounded semaglutide from $299/month and tirzepatide from $399/month on a month-to-month basis, avoiding Gala's annual commitment requirement entirely. Willow also offers a sublingual tablet option, a delivery format Gala does not have.
Willow has faced its own regulatory scrutiny over unsubstantiated advertising claims, similar to the complaint patterns seen with Gala. Read my Willow review for the full breakdown.
ShedRx
ShedRx offers the widest format range of any competitor reviewed, including injections, sublingual drops, and lozenges, versus Gala's injection-only tirzepatide. ShedRx's pricing starts around $179-249/month for semaglutide without requiring an annual commitment.
ShedRx's complaint volume on ConsumerAffairs is notably high, so it's worth weighing against Gala's own BBB concerns before choosing between them. Read my ShedRx review for the full breakdown.
NewSelf
NewSelf adds B12, glycine, or niacinamide to its compounded formulas, an approach Gala does not take, and prices tirzepatide from $144.49/month on promo, undercutting Gala's $179/month standard rate. NewSelf also offers monthly billing rather than requiring an annual plan.
NewSelf's Trustpilot review volume has drawn some suspicion of inflation on Reddit, a concern also worth considering alongside Gala's own review pattern discrepancies. Read my NewSelf review for the full breakdown.
Frequently Asked Gala GLP-1 Questions
Is Gala GLP-1 legit?
Gala is an operating telehealth platform with licensed providers, though its BBB rating and some customer service complaints are worth reviewing before signing up.
How much does Gala GLP-1 cost?
Compounded tirzepatide starts around $179/month on the standard annual plan, or $149/month for the microdose option. Brand-name Ozempic is $1,299/month.
Does Gala GLP-1 require an annual commitment?
Yes, the advertised pricing is tied to an annual plan rather than month-to-month billing.
Can I adjust my dose with Gala GLP-1?
Some patients have reported difficulty adjusting dosage after enrolling, so it's worth clarifying this directly with a provider before committing to a plan.
Does Gala GLP-1 offer brand-name medication?
Yes, Gala offers brand-name Ozempic alongside its compounded tirzepatide options.
What states does Gala GLP-1 serve?
Gala markets itself as available in all 50 states, though this has not been independently verified state-by-state.
Summary
Gala GLP-1 earns a 3.8 out of 5. Its annual-plan pricing on compounded tirzepatide is a genuine cost advantage over brand-name retail pricing, and the companion app adds real tracking value.
The annual commitment and some real customer service and BBB concerns are worth weighing before signing up, but for patients comfortable with the terms, the pricing is hard to beat.
References
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
- Frias, J. P., Davies, M. J., Rosenstock, J., Perez Manghi, F. C., Fernandez Lando, L., Bergman, B. K., ... & Nauck, M. A. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503-515. https://pubmed.ncbi.nlm.nih.gov/34170647/
- Sodhi, M., Rezaeianzadeh, R., Kezouh, A., & Etminan, M. (2023). Risk of Gallbladder and Biliary Diseases Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists. JAMA, 330(18), 1795-1797. https://pubmed.ncbi.nlm.nih.gov/37796527/
